An updated radiosynthesis of [18F]AV1451 for tau PET imaging

被引：17
作者：
Mossine A.V. [1 ]
Brooks A.F. [1 ]
Henderson B.D. [1 ]
Hockley B.G. [1 ]
Frey K.A. [1 ]
Scott P.J.H. [1 ]
机构：
[1] Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, 48109, MI
来源：
EJNMMI Radiopharmacy and Chemistry | / 2卷 / 1期
关键词：
Automated radiosynthesis; Brain PET; Flortaucipir F18; Fluorine-18; radiochemistry; Tau imaging; [!sup]18[!/sup]F]T807;
D O I：
10.1186/s41181-017-0027-7
中图分类号：
学科分类号：
摘要：
Background: [18F]AV1451 is a commonly used radiotracer for imaging tau deposits in Alzheimer’s disease (AD) and related non-AD tauopathies. Existing radiosyntheses of [18F]AV1451 require complex purifications to provide doses suitable for use in clinical imaging studies. To address this issue, we have modified the synthesis of [18F]AV1451 to use only 0.5 mg precursor, optimized the Boc-deprotection step and developed a simplified method for HPLC purification of the radiotracer. Results: An optimized [18F]AV1451 synthesis using a TRACERLab FXFN module led to high radiochemical yield (202 ± 57 mCi per synthesis) and doses with excellent radiochemical purity (98 ± 1%) and good specific activity (2521 ± 623 Ci/mmol). Conclusion: An updated and operationally simple synthesis of [18F]AV1451 has been developed that is fully automated and prepares radiotracer doses suitable for use in clinical tau PET studies. © 2017, The Author(s).
引用
收藏
相关论文
共 42 条
  • [1] Adler T.K., Albert A., Diamindenes ("Axaindoles"). Part I. Ionization Constants and Spectra, J Chem Soc, pp. 1794-1979, (1960)
  • [2] Ahmed R.M., Paterson R.W., Warren J.D., Zetterberg H., O'Brien J.T., Fox N.C., Halliday G.M., Schott J.M., Biomarkers in dementia: clinical utility and new directions, J Neurol Neurosurg Psychiatry, 85, 12, pp. 1426-1434, (2014)
  • [3] Angulo G., Carmona C., Pappalardo R.R., Munoz M.A., Guardado P., Marcos E.S., Balon M., An Experimental and Theoretical Study on the Prototropic Equilibria of the Four Carboline Isomers, J. Org. Chem., 62, pp. 5104-5109, (1997)
  • [4] Ariza M., Kolb H.C., Moechars D., Rombouts F., Andres J.I., Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future, J. Med. Chem., 58, pp. 4365-4382, (2015)
  • [5] Baker S.L., Lockhart S.N., Price J.C., He M., Huesman R.H., Schonhaut D., Faria J., Rabinovici G., Jagust W.J., Reference tissue‐based kinetic evaluation of <sup>18</sup>F‐AV‐1451 for tau imaging, J Nucl Med, 58, 2, pp. 332-338, (2017)
  • [6] Barret O., Alagille D., Sanabria S., Comley R.A., Weimer R.M., Borroni E., Mintun M., Seneca N., Papin C., Morley T., Marek K., Seibyl J.P., Tamagnan G.D., Jennings D. Kinetic Modeling of the Tau PET Tracer <sup>18</sup>F-AV-1451 in Human Healthy Volunteers and Alzheimer's Disease Subjects. J. Nucl, Med, (2017)
  • [7] Bordwell F.G., Drucker G.E., Fried H.E., Acidities of Carbon and Nitrogen Acids: The Aromaticity of the Cyclopentadienyl Anion, J Org Chem, 46, 3, pp. 632-635, (1981)
  • [8] Boutajangout A., Sigurdsson E.M., Krishnamurthy P.K., Tau as a Therapeutic Target for Alzheimer’s Disease, Curr Alzheimer Res, 8, pp. 666-677, (2011)
  • [9] Cho H., Choi J.Y., Hwang M.S., Kim Y.J., Lee H.M., Lee H.S., Lee J.H., Ryu Y.H., Lee M.S., Lyoo C.H., In Vivo Cortical Spreading Pattern of Tau and Amyloid in the Alzheimer Disease Spectrum, Ann Neurol, 80, 2, pp. 247-258, (2016)
  • [10] Choi J.Y., Lyoo C.H., Lee J.H., Cho H., Kim K.M., Kim J.S., Ryu Y.H., Human Radiation Dosimetry of [18 F]AV-1451(T807) to Detect Tau Pathology, Mol Imaging Biol, 18, 4, pp. 479-482, (2016)
12345